checkAd
    Faron Pharmaceuticals Oy Aktie
    2,7550
     
    EUR
    +5,56 %
    +0,1450 EUR
    Letzter Kurs 08:20:12 Frankfurt
    2,8050
     
    EUR
    360 STK
    Geldkurs 17:30:01
    2,8950
     
    EUR
    360 STK
    Briefkurs 17:30:01
    ISIN: FI4000153309 · WKN: A14355 · SYM: 4FR · Finnland

    Neueste Nachrichten

    Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024
    16:01 Uhr · globenewswire · Faron Pharmaceuticals Oy
    Faron Confirms Plans for the Coming Months Under New Leadership
    16.04.24 · globenewswire · Faron Pharmaceuticals Oy
    Inside Information: Additional Positive Data from the Phase 1 Part of the BEXMAB Study in Both Higher-Risk HMA-Failed MDS and r/r AML
    18.03.24 · globenewswire · Faron Pharmaceuticals Oy
    Faron to Host Webcast to Discuss latest data from Phase 1 part of the BEXMAB Study of Bexmarilimab
    14.03.24 · globenewswire · Faron Pharmaceuticals Oy
    Faron’s Financial Statement Release January 1 to December 31, 2023
    13.03.24 · globenewswire · Faron Pharmaceuticals Oy
    Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population
    25.01.24 · globenewswire · Faron Pharmaceuticals Oy
    Inside information: Faron Announces First HMA-failed MDS Patient Dosed with Bexmarilimab as part of Phase 2 of BEXMAB Trial
    09.01.24 · globenewswire · Faron Pharmaceuticals Oy
    Faron Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    03.01.24 · globenewswire · Faron Pharmaceuticals Oy
    Insider information: Faron Initiates Phase 2 Part of BEXMAB Study of Bexmarilimab in HMA-failed MDS
    06.11.23 · globenewswire · Faron Pharmaceuticals Oy
    Faron to Present Phase 1/2 Data From BEXMAB Study of Bexmarilimab in Combination with Standard of Care in Myeloid Malignancies at the 65th American Society of Hematology Annual Meeting
    02.11.23 · globenewswire · Faron Pharmaceuticals Oy
    Inside Information: Announcement of the Results of Placing, the Issue Price and registration of Placing Shares with the Trade Register
    27.10.23 · globenewswire · Faron Pharmaceuticals Oy
    Inside information: Faron Announces Positive BEXMAB Study Update in Relapsed/Refractory AML and HMA-Refractory MDS Patients
    11.10.23 · globenewswire · Faron Pharmaceuticals Oy